Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (August 2023)
19 slides from Moleculin Biotech's investor presentation, Aug 23, 2023
Slide 1: Spmourcuun
Spmourcuun We:
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: Investment Summary
Investment Summary Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Portfolio with Focus Annamycin first and foremost. Two additional portfolios (STAT-3 inhibitors ~ WP1066 - and antimetabolites - WP1122*)
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECLINICAL PHASE 1 UPCOMING MILESTONES Soft Tissue Sarcoma Lung Mets Annamycin — Acute Myeloid Leukemia Phase 1b completed in Q2 ongoing; interim data 22; Phase 2 dosing ith quarterly updates Commenced Phase 1b/2 study in Poland 03 h 2022; enrollment
Slide 5: Additional Development Pipeline
Additional Development Pipeline Adaltional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE2 UPCOMING MILESTONES. WP1056 + Radiation egic partner Plan to initiate externally funded clinical study; MTD by UK Phase 1 study wP1122 GBM/Pancrea
Slide 6: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise yymack, MD ief Medical Off x... Sy [sr Deloitte. ra Silberman, MD, Ph @ S!MOLECULIN rowaxnin W Novartis (i 5) (BAB evsarmarma
Slide 7: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds HEMATOLOGY VIROLOGY Marty Tallman, MD Richard Whitley, MD. ‘Memorial Sloan Kettering [NIH Insite of @ ‘Cancer Center. PANCREATIC sss ebiruiesta0 Jorge Cotas, wo Hongho aha MD [oute Unesiy ania School of Medicine Center woven
Slide 8: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Demonstrated 60% ORR in Phase 1 in STS; Phase 1b portion commenced Announced RP2D and efficacy of 80% ORR in last cohort of single agent AML trial; Received approval in Italy to conduct Phase 1
Slide 9: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline % of Mice with Heart Lesions ie 3935) Demonstrated to Be Non-Cardiotoxict Ability to overcome multi-drug resistance Organotrophic properties (e.g. >30x greater accumulation in lungs than doxorubicin) i. 20 30 40 20 20 40 Potent topoisomerase-I! poison with a w
Slide 10: Annamycin: Acute Myeloid Leukemia (AML) MB-106
Annamycin Acute Myeloid Leukemia (AML): MB-106 Ongoing Phase 1b/2 Trial in Combination with Cytarabine (Ara-C) Encouraging Efficacy from Completed Fist Cohort in Phase 1b Portion Preliminary CR/CE of 33%. Second Cohort Dose Deemedas Saft (n=6) in the Phase 1B portion Opened Recruitment of Phase 2 P
Slide 11: Annamycin: AML Clinical Benefit
Annamycin sate +1 Subjects in Moleculin’s clinical trials AML Clinical Benefit es c\ 63 maximum anthracycline dose established by FDA * Up to 1800 mg/m? in AML study * Up to 3420 mg/m? in STS study (to date) No cardiotoxicity has been shown in 100% 68 subjects (w/42 confirmed independently) treated
Slide 12: Annamycin: Soft Tissue Sarcoma Lung Mets MB-107
Annamycin Soft Tissue Sarcoma (STS) Lung Mets: MB-107 Ongoing Phase 2 Portion of Phase 1b/2 Trial Demonstrate Compelling Preliminary Efficacy Data Annamycin Continues os Full Phase 1b/2: 73% (n=26) Demonstrated Upcoming Milestones: * Report Phase 2 interim data * Present in-depth review of the topli
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside _—— 41K -—— 60K TNBCLung Pancreatic Liver 67K RCCLung —— 67K Endometrial Lung, STSLung Mets Initial Annamycin 104K Target Indications) Acute Myeloid potentia Annartipan Colorectal Leukemia v Liver TOTAL INCIDENCE Expansion Indications ~
Slide 14: WP1066: Flagship Immune/Transcription Modulator
WP1066 Flagship Immune/Transcription Modulator Upcoming Milestones: Report topline results from investigator- initiated Phase 1 study in pediatric brain tumors Seek external funding opportunities for an investigator-initiated clinical trials Update on IV formulation that can cross brain blood barrie
Slide 15: WP1122 Portfolio
WP1122 Portfolio Metabolism/Glycosylation Inhibitor Key Highlights Prodrug of glucose decoy enables drug-like properties Targets glycolysis and glycosylation; limits viral infectivity and replication Granted Orphan Drug Designation from U.S. FDA for treatment of GBM Open IND to initiate Phase 1 for
Slide 16: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations into the Third Quarter of 2024! ~29.8M Shares Outstanding* ~190K 3 Month Avg. Volume? Cash Balance? Bmorecuun 16
Slide 17: 2023: The Year of Validating Data
2023: The Year of Validating Data AML AML AML STS(US) | STS(EU) ¢ ¢ ¢ «6 e Commence dosing Publish CSR MB-106 Phase 2 Phase 1b/2 in Phase 1b/2 Ara-C for MB-105 cohort data interimdata interim data combination study Phase 1 results WP1122/ Arenaviruses GBM Pediatric Brain Tumors WP1096/ @ @ @ WP1066
Slide 18: Summary
Summary Focused on Annamycin clinical execution with multiple ongoing trials and multiple data readouts in 2023 & WP1066 IV formulation Upcoming data has the potential to guide Phase 2b/3 programs in STS and AML Sufficient capital to fund operations through important data milestones * Upcoming data
Slide 19: g
2 g
Moleculin Biotech — Investor Presentation (August 2023) on 6ix